VOR
Income statement / Annual
Last year (2023), Vor Biopharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Vor Biopharma Inc.'s net income was -$117.86 M.
See Vor Biopharma Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.49 M |
$8.96 M |
$4.45 M |
$1.39 M |
$91,000.00 |
$20,000.00 |
| Gross Profit |
-$3.49 M |
-$8.96 M |
-$4.45 M |
-$1.39 M |
-$91,000.00 |
-$20,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$94.32 M
|
$64.55 M
|
$47.53 M
|
$31.62 M
|
$6.20 M
|
$2.43 M
|
| General & Administrative
Expenses |
$31.72 M
|
$28.87 M
|
$21.49 M
|
$11.75 M
|
$4.22 M
|
$427,000.00
|
| Selling & Marketing
Expenses |
-$3.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.72 M
|
$28.87 M
|
$21.49 M
|
$11.75 M
|
$4.22 M
|
$427,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$126.04 M |
$93.42 M |
$69.02 M |
$43.37 M |
$10.42 M |
$2.86 M |
| Cost And Expenses |
$126.04 M |
$93.42 M |
$69.02 M |
$43.37 M |
$10.42 M |
$2.86 M |
| Interest Income |
$8.17 M |
$1.32 M |
$119,000.00 |
$29,000.00 |
$154,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.32 M |
$0.00 |
$0.00 |
$608,000.00 |
$1.00 M |
| Depreciation &
Amortization |
$3.49 M
|
$8.96 M
|
$4.45 M
|
$1.39 M
|
$91,000.00
|
$20,000.00
|
| EBITDA |
-$122.54 M
|
-$90.89 M
|
-$67.58 M
|
-$42.73 M
|
-$10.17 M
|
-$2.84 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.17 M
|
$1.32 M
|
$119,000.00
|
$29,000.00
|
-$422,000.00
|
-$289,000.00
|
| Income Before Tax |
-$117.86 M |
-$92.09 M |
-$68.90 M |
-$43.34 M |
-$10.84 M |
-$4.15 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.32 M |
-$119,000.00 |
$427,703.00 |
$608,000.00 |
-$289,000.00 |
| Net Income |
-$117.86 M |
-$90.77 M |
-$68.78 M |
-$43.34 M |
-$11.45 M |
-$4.15 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.75 |
-2.29 |
-1.85 |
-1.17 |
-0.31 |
-0.73 |
| EPS Diluted |
-1.75 |
-2.29 |
-1.85 |
-1.17 |
-0.31 |
-0.73 |
| Weighted Average Shares
Out |
$67.19 M
|
$39.55 M
|
$37.17 M
|
$37.13 M
|
$37.12 M
|
$5.66 M
|
| Weighted Average Shares
Out Diluted |
$67.19 M
|
$39.55 M
|
$37.17 M
|
$37.13 M
|
$37.12 M
|
$5.66 M
|
| Link |
|
|
|
|
|
|
